Bo-Cheng Yang

Dr. Bo-Cheng Yang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
HSHong-Wei Shi
Hong-Wei Shi
BYBo-Cheng Yang
Bo-Cheng Yang
YRYunqing Ren
Yunqing Ren
YXYi Xue
Yi Xue
Immune-mediated inflammatory diseases (IMIDs) encompass a wide range of disorders, including autoimmune, acute, and chronic inflammatory conditions, which are often characterized by immune dysregulation and excessive oxidative stress. Oxidative stress plays a pivotal role in the initiation and progression of these diseases by promoting tissue damage and sustaining inflammation. However, conventional antioxidant therapies are limited by poor bioavailability, inadequate targeting, and short-lived efficacy. In recent years, nano-antioxidants have emerged as a promising therapeutic approach due to their enhanced stability, targeted delivery capabilities, and multifunctional therapeutic effects. This review provides a comprehensive overview of recent advances in the application of nano-antioxidants in the treatment of IMIDs. Their therapeutic roles are categorized into three major groups: autoimmune diseases, acute inflammatory diseases, and chronic inflammatory diseases. In autoimmune disorders such as alopecia areata and multiple sclerosis, nano-antioxidants have demonstrated the ability to reduce oxidative damage, modulate immune responses, and alleviate clinical symptoms. In acute inflammatory conditions, including acute kidney injury and acute liver injury, these nanomaterials exert protective effects by scavenging ROS, mitigating tissue injury, and restoring organ function. In chronic inflammatory diseases such as inflammatory bowel disease and ulcerative colitis, nano-antioxidants contribute to maintaining mucosal integrity, suppressing chronic inflammation, and improving therapeutic outcomes through localized delivery and sustained release. In summary, nano-antioxidants represent a novel and promising therapeutic strategy for the management of IMIDs. Their unique physicochemical properties offer significant advantages over traditional treatments. Further research is needed to optimize their delivery platforms, evaluate long-term safety, and facilitate clinical translation.

7 June 2024 in Medicine
Verified
Journal Article
Open access
XFXuewei Fu
Xuewei Fu
HWHao Wu
Hao Wu
YSYufeng Shu
Yufeng Shu
BYBo-Cheng Yang
Bo-Cheng Yang
CDChao DENG
Chao DENG
Accumulating evidence has indicated an increased risk of acute pancreatitis in individuals with inflammatory bowel disease (IBD); however, the establishment of a clear and direct causal connection between IBD and acute pancreatitis remains uncertain. Utilizing genetic data from publicly accessible genome-wide association studies (GWAS), we conducted a 2-sample MR analysis to identify the associations between IBD, ulcerative colitis (UC), Crohn disease (CD), and acute pancreatitis risk. Rigorous quality control steps ensured the selection of eligible single nucleotide polymorphisms (SNPs) with strong associations to IBD. The primary estimation used the inverse-variance weighted method. We also assessed heterogeneity, potential pleiotropy, and conducted sensitivity analyses. The direction of causality was confirmed using the Steiger test. The MR analysis showed that IBD increased the risk of acute pancreatitis (IVW: OR = 1.032, 95% CI: 1.006–1.06, P = .015). Among the subgroup of IBD, CD (IVW: OR = 1.034, 95% CI: 1.008–1.06, P = .007) indicates a significant increase in the risk of acute pancreatitis compared to UC (IVW: OR = 1.02, 95% CI: 0.99–1.051, P = .189). The MR analysis assessing the association between CD and acute pancreatitis showed no evidence of heterogeneity or horizontal pleiotropy. Likewise, the leave-one-out (LOO) method indicated no significant influence of any individual SNP on the overall findings. In addition, the Steiger direction test revealed that CD was the cause for increased risk of acute pancreatitis, but not vice versa. In summary, this research pioneers in proposing a causal relationship between CD and acute pancreatitis among the European population.